Zynex, Inc. (ZYXI) Increases Q2 Adjusted EBITDA Estimate

Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in manufacturing and selling non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, today announced orders and an increased Adjusted EBITDA estimate for Q2 2021.

Thomas Sandgaard, CEO of Zynex said: "Our order growth in Q2 remained strong at 247% year over year and 186% for the first half of 2021. Our new reps continue to get more productive as selling returns to a more normal cadence as we emerge from COVID-19.

"The company is confirming its previous revenue estimate for the second quarter of 2021 of between $31.0 and $32.5 million. Second quarter Adjusted EBITDA is now expected to come in between $4.2 and $5.2 million compared to the previous estimate of between $3.0 and $4.0 million.

"The company's current full year 2021 revenue estimate is currently between $135.0 and $150.0 million. The revenue estimate is approximately 68% to 87% above last year's full year revenue of $80.1 million. The 2021 full year estimated Adjusted EBITDA is currently estimated between $15.0 to $25.0 million compared to 2020's full year Adjusted EBITDA of $13.7 million.

"The company will provide narrowed full year revenue and Adjusted EBITDA estimates with its Q2 2021 earnings release in late July.

"Our prescription-strength NexWave device is a healthy alternative to prescribing opioids as the first line of defense when treating pain.

"We continue to advocate for pain patients, and for physicians to prescribe our NexWave technology as the first line of defense in treating chronic and acute pain without side effects. We are dedicated to promoting our technology in an effort to remove patient addiction and other side effects from prescription opioids."

You May Also Be Interested In

• Gilead Sciences (GILD) Misses Q1 EPS by 288c
• Allison Transmission (ALSN) Tops Q1 EPS by 2c, Beats on Revenue; Offers FY24 Revenue Guidance
• L3Harris Technologies (LHX) Tops Q1 EPS by 15c; raises guidance